Cedilla Therapeutics, a company focused on broadening the reach of small molecule therapeutics to address cancer and other diseases caused by protein dysregulation, revealed on Tuesday that it has appointed Delphine Collin PhD as vice president, biomolecular sciences, to advance the company's work to develop and leverage the biophysical and biochemical understanding of ligand-induced stabilisation and degradation of therapeutically relevant protein targets.

Most recently Collin served as chief innovation officer of contract research organisation HarkerBIO. Before that, she was senior principal scientist at Boehringer Ingelheim (BI) and led a biophysics group focused on lead identification and optimisation in the small molecule drug discovery group.

Collin also started her own consulting firm, Delphine Collin Consulting LLC, while at BI, supporting companies with specialised biophysical approaches to drug discovery.

Earlier in her career, Collin was a research fellow at Merck & Co.